Skip Navigation

Nicotine & Tobacco Research 2007 9(2):233-240; doi:10.1080/14622200601080349
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ebbert, J. O.
Right arrow Articles by Hurt, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ebbert, J. O.
Right arrow Articles by Hurt, R. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 Society for Research on Nicotine and Tobacco

Nicotine Lozenges for the Treatment of Smokeless Tobacco Use

Jon O. Ebbert, M.D., M.Sc., Lowell C. Dale, M.D., Herbert Severson, Ph.D., Ivana T. Croghan, Ph.D., Donna F. Rasmussen, R.N., Darrell R. Schroeder, M.S., Mark W. Vander Weg, Ph.D. and Richard D. Hurt, M.D.

Mayo Clinic College of Medicine Rochester, MN
Oregon Research Institute Eugene, OR

Correspondence: Jon O. Ebbert, M.D., M.Sc., Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA. Tel: +1 (507) 266-1944; Fax: +1 (507) 266-7900; E-mail: ebbert.jon{at}mayo.edu


  Abstract

Nicotine lozenges have been shown to increase tobacco abstinence rates in cigarette smokers, but they have not been evaluated in smokeless tobacco (ST) users. We conducted an open-label, one-arm, phase II clinical trial to evaluate the efficacy of the 4-mg nicotine lozenge for the treatment of withdrawal and craving associated with tobacco abstinence among ST users. Eligible subjects received 4-mg nicotine lozenges for 6 weeks followed by a 6- week taper. Subjects completed daily tobacco withdrawal diaries, and data on lozenge use, adverse events, and lozenge acceptability were collected. Urine anabasine was collected at 3 and 6 months for biochemical confirmation of self-reported tobacco abstinence. Participants were 30 ST users with a mean age of 35.4 years (SD=6.5) using an average of 4.2 cans or pouches (SD=3.2) of ST per week for a mean of 15.1 years (SD=6.5). Among subjects continuously tobacco abstinent for the first 2 weeks, no significant increases in composite withdrawal symptoms were observed, compared with baseline symptoms, whereas craving decreased significantly. Biochemically confirmed 7-day point-prevalence tobacco abstinence was 53% (95% CI=34%–72%) at 12 weeks (end of treatment) and 47% (95% CI=28%-66%) at 6 months. Few adverse events attributable to the nicotine lozenge occurred, and the lozenge was perceived as helpful in assisting subjects quit ST. The use of the 4-mg nicotine lozenge appears promising for the clinical treatment of withdrawal symptoms and craving associated with tobacco abstinence in ST users. Future phase III clinical trials investigating the efficacy of nicotine lozenges are warranted.

Received: November 11, 2005; Accepted: March 10, 2006
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
R. D. Hurt, J. O. Ebbert, J. T. Hays, and D. D. McFadden
Treating Tobacco Dependence in a Medical Setting
CA Cancer J Clin, September 1, 2009; 59(5): 314 - 326.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.